Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

IMV Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

The company announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed,
byBenzinga Newsdesk
February 13, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

The company announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (“MVP-S”), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”).

  • Early analysis reveals clinically meaningful activity in refractory DLBCL patients
  • Multiple confirmed complete responses observed in heavily pre-treated patients
  • No adverse safety and tolerability signal reported, consistent with previous clinical trials
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

From Boardroom Battles To Billion-Dollar Blunders – Uncovering The Shocking Court Decision That Could Topple Elon Musk’s Reign – Tesla Down 25%

By Zaheer Anwari
February 1, 11:12 AM
A Delaware judge ruled that Elon Musk's $56 billion pay package from Tesla was excessive and improperly determined. Tesla's stock suffered an 8% decline in value with its Q4 earnings report. The legal ruling against Musk's compensation has introduced additional uncertainty, contributing to a 2% drop in stock value.

TSLA